🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

💥🚨 A tweetorial/ X'torial on the paper published today "Tissue-agnostic cancer therapies: promise, reality, and the path forward" Nature Communications Nature Portfolio 👉The Future of Cancer Treatment is Here: Tissue-Agnostic Therapies OncoAlert ASCO #ASCO25 A Thread 🧵 1/15

Kicking off ASCO #ASCO25 with a molecular tumor board session meeting incredible international #PrecisionMedicine super stars ⭐️ Eric K. Singhi, MD Ryan Ngyuen Max Christopeit #PrecisionMedicine OncoAlert 🚨

Welcome to #ASCO25 ! On behalf of the🚨OncoAlert Network—hello from Chicago! 🌆 🔗 Sign up the Newsletter: oncoalert.m-pages.com/nhMpwe/oncoale… WE ARE ALL OncoAlert 🚨 For 7 years, we've brought you real-time updates from the biggest oncology congresses. This year, we’re back with: 🔹

The OncoAlert🚨DAILY Newsletter at #ASCO25, REGISTER HERE 👉 OncoAlert360.com OR buff.ly/p0O1gZ8 OUT TOMORROW MORNING!!! The OncoAlert Network will be delivering a daily newsletter to oncologists worldwide during ASCO 2025 — featuring our top trial picks from

In just 45 min… #TheOncoAlert5k 🏃 Come join us We leave 7am in front of the McCormick, up the lake to the Chicago river and return to the same place See you here !! #OncoAlertAF Dra. María Natalia Gandur Quiroga Alizée Camps - - Maléa Biagio Ricciuti, MD, PhD Emre Yekedüz Hidehito HORINOUCHI Fadi Haddad, MD

TEDOPAM - maintenance randomised phase 2 vaccine trial #PDAC Induction mFFX- Folfiri vs Folfiri+ OSE2101 (TAAs) ➡️106 pts ➡️met primary endpoint of 12mth OS>50%; ➡️But control arm mOS 17 vs vaccine arm 15mths ➡️highlights benefit maintenance approaches ASCO OncoAlert #ASCO25

🔥NeoPancOne🇨🇦 ➡️mFFX in resectable PDAC ➡️exploring GATA6&subtypes ➡️mEFS &OS 16.3 &34.2mths ➡️1yr EFS 90% in GATA6 hi vs 50% lo ➡️1yr OS classical 95% vs.57% basal-like ⭐️Time to subtype upfront in all PDAC recognising plasticity OncoAlert #ASCO25 Ontario Institute for Cancer Research (OICR) Princess Margaret Cancer Centre

Dear Colleagues at #ASCO25 As ALWAYS, it is a pleasure for OncoAlert 🚨 to be around to capture yet another GREAT Uromigos discussion by Tom Powles 🇬🇧& Brian Rini, MD 🇺🇸 Here they are lakeside discussing Final Results of IO-Based Combination in mRCC Ping OncoAlert GU Faculty

It’s been an absolute pleasure to be part of this ASCO ESMO - Eur. Oncology session during #ASCO25 - in order to deliver the best care to our #patients we need equitable, scalable and sustainable solutions based on solid evidence. #PrecisionMedicine OncoAlert 🚨

Newly-released ESMO recommendations critically assess specific germline pathogenic variants in terms of cancer-related mortality and testing implications for patients and their families Read the full article in the #ESMODailyReporter 🔗 ow.ly/xpGT50W9PuY

Great overview of #PrecisionMedicine in #PDAC by Eileen M O’Reilly at ESMO - Eur. Oncology #ESMOGI25 If you missed it, please watch it 📺 🧬NGS important, with RNA for fusions 🫶KRAS 🤞🏻MTAP 👀Claudin 18.2 🤝Molecular Tumor Board-ESMO recomendations available #ESMOAmbassadors Ben Westphalen

Ben Westphalen delivered compelling insights into diving deep into the #BRAF pathway in colorectal cancer. #ESMOGI25 By spotlighting targeted 👉🏻 approaches, he underscored how ❗️pathway-focused research opens the door to more precise, high-impact treatments!! ESMO - Eur. Oncology

A very important step in the right direction by the European Commission which will help to improve #CancerCare in #Europe 🇪🇺

🚨Happy 4th everyone! Delighted to share with the🌎our comment just published in Lancet Oncology The Lancet Oncology The Lancet on “Bridging Classification & Treatment” 👉🏼 🧬 Tumor biology > tumor location. It’s time we evolve WHO cancer classification to match how we treat it: by

The relevance of a WIDE molecular profiling in #PDAC and #BiliaryMalignancies Our data from Fundación Jiménez Díaz presented at ESMO - Eur. Oncology #ESMOGI25 👉Targets in PDAC are identified when wide pannels are used-regardless of KRAS 🧬MTAP loss present both in PDAC and BTC #ESMOAmbassadors

🔬 Discover the ELCAP framework—a 3-tier guide to using Large Language Models #LLMs in clinical practice. 👉 Register now with your free ESMO account: 🔗 ow.ly/fY1m50WnyGJ

Genomic context of NTRK1/2/3 fusion-positive tumours from a large real-world population [Jul 20, 2021] Ben Westphalen et al. npj Journals Precision Oncology ow.ly/jDyt50FDVB0 #PrecisionMedicine #RWD #openaccess FoundationCORE® database of >295,000 cancer patients